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Summary
Background Eliminating hepatitis C requires address-
ing issues other than medicines or therapies. Public
health policies focused on the hepatitis C virus (HCV)
must be emphasized and worked to know the impacts
on its epidemiologic dynamics. This research aims to
provide a tool to evaluate and simulate alternatives
by redefining policies meeting specific needs in each
country towards the HCV elimination target by 2030.
Methods The development of a gamified model with
24 public health policies focused on HCV was con-
ducted to evaluate the impact of measures in the dis-
ease epidemiologic dynamics. The Let’s End HepC
(LEHC) project encompassed key populations (peo-
ple who inject drugs [PWID], prisoners, blood prod-
ucts and remnant population) in Austria and other
countries, presenting prospects for every year from
2019 to 2030. The LEHC epidemiological model com-
prised an integrated solution for HCV, with adaptive
conjoint analysis (ACA) and Markov chains constitut-
ing its main processes.
Results Despite Austria’s efforts towards achieving the
HCV elimination goal by 2030, the LEHC model fore-
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cast quantitative analysis predicts that it is still not
enough to meet the target; however, prospects are
very optimistic if public health policies are adapted
to the country’s needs, being possible to achieve the
goal as early as 2026.
Conclusion In Austria, the LEHC tool allowed to fore-
cast the HCV elimination year anticipation to 2026,
instead of being achieved after 2030. This target will
only be valid if adequate management of the 24 pub-
lic health policies focused on this pathology is further
implemented.
Keywords Hepatitis C · Modeling · Public Policies ·
Public Health · Gamification
Abbreviations
ACA Adaptive conjoint analysis
DAA Direct acting antiviral
EMCDDA European Monitoring Centre for Drugs
and Drug Addiction
F0–F4 Metavir stages
HCV Hepatitis C virus
HIV Human immunodeficiency virus
ICS/UCP Healthcare Sciences Institute/Catholic
University of Portugal
KOL Key opinion leaders
LEHC Let’s End HepC
NAB National Advisory Board
PWID People who inject drugs
RIC Retain in care
SVR Sustained virologic response
Tx1 first treatment for chronic hepatitis C
Tx2 The probability of an infected individ-
ual being retreated against HCV if al-
ready retained in care and previously
treated
WHO World Health Organization
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Introduction
Hepatitis C is a silent disease that afflicts people all
over the globe. This virus affects people according
to unknown timetables, which imposes an important
role on health services in terms of human resources,
technology and capital. Its evolution is well-docu-
mented in the natural history of the disease [1].
Globally, the hepatitis C virus (HCV) is the seventh
leading cause of hepatic mortality [2], often related to
hepatocellular carcinoma. Transmission networks of
the disease are often associated with significant costs,
either being liver transplants or indirect costs.
One of the HCV characteristics is its concentration
of higher prevalence rates among given population
segments: people who inject drugs (PWID) [3–5], peo-
ple who have been incarcerated [6–8], individuals who
have received blood products [9, 10].
To address the public health issue of HCV, the
WHO has defined an elimination goal for the dis-
ease by 2030, aiming at reducing disease incidence
by 90% and mortality by 65% [11]. This target has
set the discussion about targeting population groups
that are more prone to be infected, with the con-
cept being characterized as micro-elimination. There
are currently over ten groups that meet this crite-
rion [12]: individuals with Aboriginal and indigenous
background, people born in specific periods, chil-
dren whose mother was infected with HCV during
pregnancy, hemodialysis patients, individuals coin-
fected with HCV/HIV, PWID, migrants from high HCV
prevalence countries, people who have received blood
products, prisoners, transplant recipients, war veter-
ans [13], baby boomers [14], among others.
Projections for the HCV prevalence have been con-
sidered to be between 0.5% and 3.5% in Europe [15,
16] and 7–8% [17] in other continents. The presented
values have been subject to updates in epidemiologi-
cal revisions [18], with a decrease in HCV prevalence
rates being verified to be 0.2–1.5% in Europe [19].
In Austria, it has been estimated that the prevalence
of HCV infections was 0.46%, and the prevalence of
viremic prevalence around 0.34% in 2008 [20]. For this
reason, including Austria in the first modeling phase
of the LEHC project was seen as essential.
The LEHC tool aims to evaluate and simulate di-
verse adaptations of public health policies according
to the modeled epidemiological characteristics of the
disease and the needs of a country to achieve the HCV
elimination goal by 2030. By modeling the impact of
the dynamics between both referred elements, it is
possible to generate a landscape on HCV epidemiol-
ogy for every year until 2030. Therefore, the model is
also aligned with the sustainable development goals
timetable. The study of the 24 health policies impact
and their different levels of implementation resulted
in different estimates on HCV epidemiology for differ-
ent population groups: PWID, blood products, vertical
transmission1, remnant population. The natural his-
tory of HCV is reflected in the indicators that result
from the epidemiological dynamics on model projec-
tions.
This project is being promoted by the Public Health
Unit of the Health Sciences Institute of the Catholic
University of Portugal. Along with Austria, other coun-
tries were included in the project’s initial modeling
phase (Romania, Bulgaria, Portugal, Spain) while oth-
ers are also being currently worked.
Methods
The LEHC model has the potential to forecast and
gamify2 different applications of public health policies
while calculating its impacts on HCV epidemiology.
It is possible to assess the modeling results for six
population groups: remnant population, prisoners,
PWID, blood products, vertical transmission and total
population. The remnant population was calculated
according to the formula: remnant population= total
population– (blood products population+ prisoners
and ex-prisoners+PWID and ex-PWID). Due to its
low number, the vertical transmission population was
included in the remnant population.
The LEHC epidemiologic model integrated a total
of 1100 active Markov chains3 branches among the
identified population groups, which resulted in data
that characterize the HCV epidemiological evolution.
Health states and respective transition probabilities
are also included in the branches system, being de-
fined according to the natural history of HCV as iden-
tified by Salomon et al. [1] in 2003. The Markov chains
component is applied for the period between 1950
until the present time, featuring data that correspond
to indicators, such as incidence/prevalence rates as
well as diagnosis, retain in care, treatment and sus-
tained virologic responses (SVR) rates. The availability
of data regarding epidemiological indicators for HCV
is linked with research in the mid-1990s, driven by the
ground-breaking hepatitis C virus discovery in 1989.
As a result, when no data were available or the existing
information did not meet the full criteria for the statis-
tical series, proxies were produced to atone the mod-
eling components. Proxies were contemplated as as-
sumptions, being assessed and validated by the coun-
try’s National Advisory Board (NAB) and were sub-
ject to the mathematical evaluation by comparing the
model results with empirical data.
It is assumed that the statistical data used for the
LEHC model are correct, considering that they are ei-
ther collected from peer-reviewed journals or have
1 HCV transmission from pregnant mother to child.
2 Simulator that in a technologically opaque way allows the user
to create and test results over time for theoretical scenarios.
3 Mathematical tool that uses successive multiplications for de-
scribing a phenomenon with time existence, and simultaneously
with topologic intersection over the time variable.
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their source in official data of countries or regions.
In the case where it was not possible to retrieve data
from these sources, proxies had to be produced, with
the assumption that the leading experts in each coun-
try of the LEHC project are able to provide an accurate
overview of the epidemiological reality.
However, it is known that even data that were sub-
ject to peer review have often existed solely in micro-
populations while being related to the methodology
used in data collection. It must be noted that even
official data from countries has some frailties, such
as the difference of the total number of inhabitants
by over one million individuals, the source or coun-
try on the origin of the data, the opinion of the most
acknowledgeable experts, which is always a personal
view based on vast experience.
Around 100 key opinion leaders (KOL) from each
NAB have also participated in surveys based on an
adaptive conjoint analysis (ACA) approach, taking
a global average of 2h for completion. The resulting
data were used to develop the modeling component
related to the 24 public health policies (additional
details in htttp://www.letsendhepc.com/)4 in each
country. These policies have a distinctive scale of
implementation being contemplated on the surveys,
in which every KOL attributes a different weight to
different policy levels. This process allows the dif-
ferentiation of forecast results by having distinctive
impacts on the Markov chains component, according
to a cure cascade5 perspective. Modeling in Austria
was supported by the participation of seven KOLs in
completing the ACA surveys.
Model construction and data support
Total population, remnant population and vertical
transmission population
Austria’s demography for the total population, rem-
nant population and vertical transmission was con-
structed by accessing data from the Statistics Austria
website [21] concerning the country’s total popula-
tion, live births and residents with foreign citizenship
[22]. For each year, the total population should be
the sum of last year’s total population plus the num-
ber of individuals who enter the population minus the
number of individuals who leave the population.
For the background mortality series, the annual
probabilities of death were also based on data from
the Statistics Austria website [23].
4 Additional information is available in the preprint article un-
der submission “LEHC—Public Health Policies impact in HCV
epidemiological modeling: a tool towards a micro-elimination
path.” [33].
5 Strategy to approach pathologies used in public health, in gen-
eral by all major health organizations that is based on successive
and logical focal points of disease management: awareness, pre-
vention, diagnostics, linkage to care, treatment, reintegration.
New chronic HCV infections and HCV prevalence
rates were extrapolated and adapted to a national per-
spective of Austria [20], being aligned with two other
scientific reports [24, 25].
The vertical transmission comprised HCV inci-
dence values that represented the total cases of HCV
positive live births, being included in the remnant
population. Based on the availability of data it was
considered that there is a total of 19 or 20 cases
in Europe per year. The values were adapted and
extrapolated to fit Austria’s reality [26].
In Austria, hepatitis C-related diagnostic tech-
niques were assumed to have begun implementation
in 1997 [20]; therefore, a rate of 0% was applied to
previous years. For the following years, diagnosis rates
were presumed to be equal for both genders and for
all the age groups, according to the Metavir score
system, 5% in fibrosis stages F0–F3, 7% in F4, 95% in
decompensated cirrhosis and 70% in hepatocellular
carcinoma stage.
No data were found regarding the annual proba-
bility of a diagnosed patient being retained in care.
Therefore, it was decided that the Portuguese data [27]
for this indicator should be used to effectively repre-
sent the Austrian population.
In Austria, HCV treatments (Tx1) [20] were as-
sumed to have started in 1997 in relevant numbers.
Recent direct-acting antiviral (DAA) treatments (Tx2)
[20] were assumed to have started in 2014. Data
regarding SVR rates for patients who followed each
treatment were also extrapolated from the study by
Schaefer et al. [20].
PWID population
The PWID demography was based on two reports [28,
29], with values being estimated by regression anal-
ysis. For the period between 2019 and 2030, values
were aligned with the trend from previous years. In
order to determine the number of individuals who
start/stop injecting drugs each year, data from the
“Suchthilfe Wien” (personal communication, unpub-
lished data, https://suchthilfe.wien) were used along
with the aforementioned reports.
Data regarding the annual probability of death
were based on the working group drug-related fatal-
ities (2017) report (“Arbeitsgruppe drogenbezogene
Todesfälle (Sterbejahr 2017)”, [30]) for the period be-
tween 2003 and 2017. Considering the identified
trend, data for the missing years were accordingly
aligned.
Values for HCV prevalence and HCV incidence
were based on scientific reports [28, 29]. A report
from the EMCDDA [31] estimated a prevalence of
30,000–33,000 high-risk opioid users in Austria. The
percentage of chronic HCV infections ranged from
13–83% in 2017.
Diagnosis rates were considered to be 0% before
1997. For the following years, diagnosis rates were
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produced according to data from the “Suchthilfe
Wien” (personal communication, unpublished data,
https://suchthilfe.wien). For the period between 1997
and 2018, diagnose rates for both genders, and all age
groups were assumed to be 1% for F0–F4 stages and
80% for decompensated cirrhosis and HCC stages.
The annual probability of an individual being re-
tained in care if the Hepatitis C was already diagnosed
was determined in statistical series under qualitative
advice of the NAB in Austria.
The annual probability of an infected individual to
be treated for the first time against HCV if already
retained in care was based on the “Suchthilfe Wien”
(personal communication, unpublished data, https://
suchthilfe.wien). Until 1996 it was assumed that ther-
apies were not yet available.
As for the annual probability of an infected individ-
ual being retreated against HCV if already retained in
care, data were based on the “Suchthilfe Wien”. It was
assumed that DAA therapies were not yet available
before 2014. For the period between 2014 and 2018,
a rate of 20% was assumed for both genders and age
groups in each stage of liver disease.
The success rates of the patient’s first treatment and
retreatment with DAA therapies were determined un-
der the qualitative advice of the Austrian National Ad-
visory Board.
Prisoners population
Data retrieved from the Ministry of Justice [32] were
used to produce the demography’s statistical series
for the prison population. For the period between
1950 and 1982, data were considered to be constant,
while between 2019 and 2030, the trend observed in
previous years was adapted and used as a reference.
For the period between 1950 and 2030, data con-
cerning this population’s background mortality was
based on the values used in the remnant population
regarding the same indicator. It was assumed that the
probability of death while in prison was three times
higher as compared to the general population.
It was assumed that 1% of all prisoners were newly
infected with HCV each year, for the period between
1950 and 2018. It was assumed that 15% of all prison-
ers were chronically infected with HCV.
Annual probabilities of an infected individual being
diagnosed were produced according to the qualitative
advice of the National Advisory Board in Austria.
Until 1996 it was assumed that retain in care (RIC)
was not feasible. Data from the Ministry of Justice
(oral communication, unpublished data) were used
for the period between 1997 and 2018. The RIC rates
for both genders and all age groups were assumed to
be 20% for F0–F4 stages, 70% for decompensated cir-
rhosis stage and 60% for the hepatocellular carcinoma
stage.
Annual probabilities of individuals being treated for
the first time and/or retreated for HCV, along with
the respective sustained virologic response rates were
produced under the advice of the National Advisory
Board.
Blood products population
This population group encompasses the total number
of individuals that have ever received a blood transfu-
sion.
Demography values were based on data from Red
Cross Austria (https://www.roteskreuz.at/). A total of
350,000 blood products were used in 2017. It was esti-
mated that each patient who receives blood products
uses an average of three blood preserves, according
to clinical estimates. Values were assumed to be in-
creasing in the period between 1950 and 2010. Due to
the implementation of new programs and therapies, it
was assumed that, for the remaining years, a decreas-
ing rate should be applied to the identified trend.
The background mortality rates were considered to
be similar to those in the remnant population. Con-
sidering that blood screening for transfusions was in-
troduced in Austria in 1990, data were accordingly ad-
justed to represent its impact on mortality.
It was assumed that half of the HCV infected pop-
ulation in Austria was due to blood products during
the period between 1950 and 1983. The probability
of infection by HCV was based on an extrapolation
from the general population values. For the period
between 1983 and 1990, a decrease was applied in or-
der to reach a probability of infection by HCV value of
0.001. This value is expected to have remained con-
stant for the remaining years.
HCV prevalence values are assumed to be of con-
stant increment for the period between 1950 and 2010,
decreasing in the following years in order to be aligned
with a prevalence of around 3% of the blood products
population in 2018.
Diagnosis rates were assumed to be equal to the
ones used for the remnant population. In the period
between 1997 and 2018, values for both genders and
all age groups were assumed to be 5% from F0–F3
stages, 7% in the F4 stage, 95% in decompensated
cirrhosis stage and 70% for hepatocellular carcinoma
stage.
Retain in care values were also assumed to be the
same as in the remnant population. A rate of 80% was
considered for all liver disease stages in both genders
and all age groups.
The annual probability of an individual being
treated for the first time and/or retreated against
HCV if retained in care was assumed to be the same
as for the remnant population. The same process was
conducted with SVR of first treatment and retreat-
ment.
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Fig. 1 Modeled HCV prevalence for the studied populations
in Austria. a Total population summary. b Remnant popula-
tion and vertical transmission. c PWID+ex-PWID. d Prison-
ers+ ex-prisoners. e Blood products. The presented values
(thousands) consider the forecast of current policies in Aus-
tria remaining unchanged for the period between 2019 and
2030. Comparison with the elimination target for each popu-
lation (total population, remnant population, vertical transmis-
sion, blood products, prisoners, PWID)
Results
Epidemiological indicators
In Austria, the model results for the current year (i.e.,
2019) appoint a total population of 8,679,051 individ-
uals, with 29,348 being infected with HCV and an oc-
currence of 607 new cases is to be registered. Forecasts
show that in 2019 around 16,626 individuals will be di-
agnosed, with 12,402 being linked to care, from which
5836 will be under treatment and 1064 cured cases
are expected to happen. As for the different liver dis-
ease stages, model results for this year show that there
will be 4934 cases of compensated cirrhosis, 337 de-
compensated cirrhosis and 206 cases of hepatocellular
carcinoma. In addition, 11 liver transplantation cases
are expected, as well as 202 liver-related deaths.
The LEHC model forecasts that HCV elimination
will not be achieved by 2030 (see Fig. 1). In that
year, the total population is expected to comprise
8,532,313 individuals, from which 4261 are infected
with HCV and 607 are estimated to be new cases. Con-
sidering the pool of HCV infected individuals, around
2621 are predicted to be diagnosed with 1883 being
linked to care. As a result, in 2030, 784 individuals are
expected to be on treatment. In the same year, 810 in-
dividuals should be cured. Concerning the different
liver disease stages, the model forecasts 4351 cases of
compensated, 104 cases of decompensated cirrhosis
and 82 cases of hepatocellular carcinoma. Due to
the burden of disease, 3 liver transplantations are
expected to be conducted, and it is estimated that
there will be 82 cases of liver-related deaths.
Modeled HCV prevalence by population
The LEHC model estimates that HCV prevalence val-
ues will steeply decrease until 2025 and slightly de-
crease until 2030. Assuming the elimination line as
10% of the modeled HCV prevalence value in 2015,
the WHO target will not be achieved by 2030 (see
Fig. 1). Despite modeled HCV prevalence values for
2030 being very close to reaching the elimination line,
the worst-case scenario was considered in the face
of an uncertainty zone as a conservative reading of
results. This reading was based on not incurring in
risks of indicating results that could influence deci-
sion-makers, legislators and national health authori-
ties to over-alleviate public health policies focused on
Hepatitis C. The two points of uncertainty that can
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improve this reading will be to define more accurately
the real number of HCV infected individuals in Aus-
tria in 2015 (reference value for the WHO elimination
target by 2030), which in the case of Austria is particu-
larly fragile compared to the remaining five countries
participating in the LEHC project. Also, forecasting for
a 12 years period implies a high uncertainty margin,
reason why the LEHC project seeks to revisit national
data, whenever there is new concrete data that allows
to recalibrate the model.
Modeled HCV prevalence values for the remnant
population and vertical transmission are expected to
slightly decrease over the years. The elimination target
for this population will not be achieved by 2030 (see
Fig. 1).
As for the blood products population, HCV preva-
lence is also expected to decrease over the years. Ac-
cording to the LEHC model, the WHO target for this
population will be achieved in 2025 (see Fig. 1).
HCV prevalence for the prisoner population is ex-
pected to steeply decrease until 2025 and slightly de-
crease over the remaining years. HCV elimination will
not be achieved by 2030 in this population (see Fig. 1).
It is expected that HCV prevalence values for the
PWID population will gradually decrease until 2027
and slightly decrease over the remaining years. HCV
elimination will not be achieved by 2030 for this pop-
ulation (see Fig. 1).
Policies
Forecast results from the first version of the LEHC
model indicate that if there are no changes in the 24
public health policies in Austria, HCV will not be elim-
inated in the country by 2030. On the other hand, it
is still possible to improve 9 of the 24 public health
policies (see Table 1 and Appendix, Table 2).
It is possible to achieve the same result by 2028
if a national strategy that includes the evaluation of
available resources and clinical evaluation is imple-
mented.
In addition to the changes in the aforementioned
policies, it is possible to achieve an earlier HCV elimi-
nation by fully implementing sets of three other poli-
cies that focus on the dimensions of awareness and
prevention. For example, this result can be achieved
by extending the legal framework in terms of discrim-
ination of patients with HCV. It could also include ac-
cess to services, social and public facilities, instead of
just having a labor framework; by developing and fully
adopting the national policy to address the prevention
of HCV infection and finally, by implementing a pol-
icy of impeditive donation in screening for HCV in
tissue and organ donations, instead of not hindering
donation.
By fully implementing all the 24 policies in Austria,
the model results present the possibility of achieving
HCV elimination by 2026. For that year, according
to this optimal prospect, there will be a total popu-
Table 1 Public health policies differential gains on the re-
duction of HCV infection cases in total population, in 2030,
if fully implemented
Policy impact on total population in 2030
Public health policies Reduction in HCV
infection cases
National strategy that includes the HCV (evalua-
tion of available resources)
913
National strategy that includes the HCV (clinical
evaluation)
761
National policy to address the prevention of HCV
infection
470
Legal framework particularly in terms of discrimi-
nation of patients with HCV
385
Screening for HCV in tissue and organ donations 234
Routine screening of HCV in pregnant women 108
Screening in the general population 98
Test sites/screening HCV outside the hospital
environment
75
Risk reduction services in prisons 10
The reduction in HCV infected cases, in each policy, are not cumulative
The represented value illustrates the impact that each policy, if fully
implemented, can have in the estimates for the year 2030
The policies in this table are organized by impact level on the reduction of
HCV infection cases, in descending order from top to bottom
lation of 8,596,428 individuals. HCV incidence val-
ues are expected to be 343 cases and HCV prevalence
around 2632 HCV infected individuals. The model
also forecasts 1927 diagnosed individuals, with 1587
being linked to care and 756 enrolled in treatment.
In the same year, estimates indicate 982 cured cases.
In relation to liver disease stages, the model predicts
4685 compensated cirrhosis, 142 decompensated cir-
rhosis and 99 individuals with hepatocellular carci-
noma. It is expected that 4 liver transplants are con-
ducted, and an occurrence of 108 liver-related deaths
is to be registered.
Considering the full implementation of the 24 poli-
cies in Austria, it is possible to achieve additional ben-
efits for the years after 2026. A decrease in the total
population is appointed by the LEHC model for 2030,
presenting 8,532,441 individuals in Austria. HCV in-
cidence values remain the same, with 343 new infec-
tion cases. HCV prevalence is forecast to significantly
decrease, with 1843 HCV infected individuals. The
model appoints 1153 diagnosed patients, with 885 be-
ing linked to care and 384 on treatment. In that year,
results appoint for 386 cured individuals. In relation
to liver disease stages, it is forecast that there will be
close to 4109 cases of compensated cirrhosis, 82 cases
of decompensated cirrhosis and 71 cases of hepato-
cellular carcinoma. Finally, themodel results show the
possibility of 2 liver transplantations being conducted
as well as the occurrence of 67 liver-related deaths.
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Table 2 Main Public Health Policies differential gains in reducing HCV infection cases, in 2030, if fully implemented, by
population
Main policy impacts in reducing HCV infection cases in 2030
Public health policies Remnant population Blood products Prisoners PWID
National strategy that includes the HCV (clinical evaluation) 159 1 39 658
National strategy that includes the HCV (evaluation of available re-
sources)
153 1 38 723
National clinical guidelines for the diagnosis and treatment of HCV 78 n.a. n.a. n.a.
Legal framework, particularly in terms of discrimination of HCV patients 74 0 18 367
National policy to address prevention of HCV infection n.a. 0 23 447
Screening for HCV in tissue and organ donations 57 0 11 223
Risk reduction services available in prisons 0 0 10 0
HCV testing/screening sites outside of the hospital environment 11 0 4 72
General population screening 38 0 0 98
Routine screening of HCV in pregnant women 42 0 0 108
The reduction in HCV infected cases, in each policy, are not cumulative
The represented value illustrates the impact that each policy, if fully implemented, can have in the estimates for the year 2030
n.a. not applicable
Discussion
Modeling hepatitis C in Austria was based on gathered
data from multiple sources, such as national entities
(Statistics Austria, Suchthilfe Wien, Ministry of Jus-
tice, Red Cross Austria, etc) [21–23, 32]. and published
studies [20, 24, 25, 31]. When no data were found to
complete statistical series elements such as specific
years, stratification by age or by gender, proxies were
produced as detailed in the methodology. Estimates
were based on both national and international stud-
ies regarding the populations covered by the LEHC
project: Remnant population and vertical transmis-
sion [20, 24–26], people who inject drugs [28, 29, 31],
prisoner populations [32], blood products population.
Empirical evidence resulting from the LEHC project
corroborates the view that the path for eliminating
hepatitis C until 2030 requires a higher focus on find-
ing and maintaining patients within the grasp of the
healthcare system. Given the high prevalence and
incidence rates among population groups, such as
PWID and prisoners, it is important that measures
focus on the micro-elimination concept.
It is also important to consider the risk of over-
lapping populations, especially between PWID and
prisoner populations, and to a much lesser extent be-
tween PWID and blood products. It was not possible
to find published epidemiological data that could sep-
arate these populations in the remaining LEHC coun-
tries. As a result, in the modeling process, a proxy was
created whereby it is assumed that about 60% of the
prison population would have been HCV-infected in
the past by i.v. drug use, subtracting this number from
the PWID population. A similar situation was applied
to the relationship between blood products and PWID,
seeking to correct double interpretation situations.
Considering the modeling results, there are several
situations in which the number of patients with com-
pensated cirrhosis is higher than the total number of
HCV infected individuals. This situation is verified
as people who are successfully treated for HCV will
still have pre-existing conditions such as the cirrhotic
state. Considering the increasing number of people
undergoing treatment and thus cured, it is natural
that even with new HCV infection cases, in a given
moment there will be less HCV infected individuals
than individuals with compensated cirrhosis.
In addition, diagnosis and linkage to care measures
are paramount to meet the HCV elimination target,
being aligned with the sustainable development goals.
In Austria, it has been confirmed that 15 out of the
24 public health policies considered for the study are
currently fully implemented.
Despite the fact that other countries are also in-
cluded in the LEHC project, it was considered that
introducing external readings of comparison between
country policies and epidemiological indicators could
be an inducement of bad practices for health authori-
ties. In the LEHC project’s developed work in 12 coun-
tries, the dynamics of public health policies were ver-
ified to be very independent, even in common issues.
Conclusion
The LEHC project accomplished the modeling of hep-
atitis C in terms of public health policy impact on
the disease epidemiology for the remnant population
and other population groups in Austria. The dynamics
of this tool allowed the gamification of public health
policies, which provided an insight into how different
extents of specific measures have an impact on the
HCV epidemiology.
This model has the ability to forecast the extent to
which a specific public health policy might exert in-
fluence on a particular population group, in a pool
of 24 public health policies focused on HCV consid-
ered in the LEHC project. This is essential in iden-
tifying patterns that have the potential to not only
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allow countries to address given policies to achieve
the HCV elimination goal by segmenting the popula-
tion but also to know the why, who, what, where and
when. The tool allows rehearsing public health policy
concepts before implementing them in the field, thus
anticipating the outcomes.
In the light of the cure cascade system, modeling
results appoint awareness and prevention as the di-
mensions in which public health policies might have
the broadest impact in lessening HCV prevalence val-
ues in Austria. Therefore, given these areas of influ-
ence, there is a clear indication that achieving the HCV
elimination target will require additional efforts be-
sides medication development. Diagnosing HCV in
individuals who are unaware of their condition and
linking them to healthcare services will determine the
success of achieving the HCV elimination goal.
According to the modeling results, the elimination
target will not be met by 2030 in Austria. Nonetheless,
in the case that all the 24 public health policies are
fully implemented, it will not only be possible to meet
the elimination target, but it might happen as soon as
2026. As a result, it is seen that policies are funda-
mental in providing insights into combating HCV in
order to achieve its elimination.
Research limitations
The quality of the modeling always depends on data
quality used as input, on the quality of the analysis
and on the knowledge about the public health poli-
cies’ impact in the field. In LEHC (or any othermodel),
it is paramount to deal with the issue of quality as well
with data availability.
Since there are no confidence intervals in model-
ing, the fitting test was performed by overlapping the
results obtained by the LEHC modeling tool, on the
known epidemiological curve or admitted into a given
geographic region, in this case, a country. In the LEHC
tool, only countries where this curve was at least 95%
similar in the previous years were selected for publish-
ing data; however, it must be noted that even national
data are often limited in their reading due to being ei-
ther very regional (in the case of Austria, most of the
information comes from Tyrol), from samples some-
times incident on populations that do not represent
the country (studies with prisoners or PWID), or epi-
demiological studies that do not cover the entire pop-
ulation. This dependence on adjusted fitting based on
known epidemiological evidence is a limitation of the
tool, but endogenous to the modeling process. No
country which worked in the LEHC project showed
strong robustness of epidemiological data.
Considering that the LEHC model was based on
the best available data from Austria, it is also impor-
tant to state that obtaining national data was chal-
lenging, which imposed the need of producing proxies
from Austrian regions, to extrapolate and interpolate
national data, and to create statistical series having
proxies as a basis composed by other secondary data
series. Therefore, the Austrian LEHC model is the
best possible to achieve, considering the data avail-
able. A call for action on the research and publication
of epidemiological data regarding hepatitis C in Aus-
tria is of the utmost importance in filling in data gaps.
This project is fully available to analyze and integrate
all data that the scientific community provides for this
project.
In perspective, the dynamic vision for this project
should contemplate an annual review for integrating
new official data and other epidemiological data that
might have been produced in the meantime. Sim-
ilarly, the authors comprise the modeling results of
LEHC for 31 December 2018, in which it is based on
statistical data available up to the referred data and
this being designated as “LEHC: An integrated solu-
tion for HCV—application in Austria”.
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